"
Team:LIKA-CESAR-Brasil/Hybridization
From 2014.igem.org
(Difference between revisions)
| Line 299: | Line 299: | ||
<li><a href="https://2014.igem.org/Team:LIKA-CESAR-Brasil/Safety">SAFETY</a></li> | <li><a href="https://2014.igem.org/Team:LIKA-CESAR-Brasil/Safety">SAFETY</a></li> | ||
<li><a href="https://2014.igem.org/Team:LIKA-CESAR-Brasil/Atribuitons">ATRIBUITIONS</a></li> | <li><a href="https://2014.igem.org/Team:LIKA-CESAR-Brasil/Atribuitons">ATRIBUITIONS</a></li> | ||
| + | <li class="igem-logo"><a href="https://2014.igem.org/"></a></li> | ||
</ul> | </ul> | ||
</div><!--/.nav-collapse --> | </div><!--/.nav-collapse --> | ||
Revision as of 02:10, 18 October 2014
NOTEBOOK
Hybridization Process
To perform the hybridization process, 3μL target synthetic solution (miRNA) at different concentrations (1x10-6 the 1x10-12M) was dropped on the working electrode. The electrode remained under 300 rpm agitation at a temperature of annealing of 52 ° C for 10 minutes (the description of the manufacturing company sequence). Tests positive for breast cancer provided by the Baron of Lucena-PE Hospital biological samples were also performed. After completion of the hybridization tests with different targets, hybridization tests with non-complementary targets were made.
